Invex Therapeutics (ASX:IXC) Days Payable : 0.00 (As of Dec. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Days Payable?

Invex Therapeutics's average Accounts Payable for the six months ended in Dec. 2024 was A$0.24 Mil. Invex Therapeutics's Cost of Goods Sold for the six months ended in Dec. 2024 was A$0.00 Mil.

The historical rank and industry rank for Invex Therapeutics's Days Payable or its related term are showing as below:

ASX:IXC's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 118.245
* Ranked among companies with meaningful Days Payable only.

Invex Therapeutics's Days Payable stayed the same from Dec. 2023 (0.00) to Dec. 2024 (0.00).

Invex Therapeutics Days Payable Historical Data

The historical data trend for Invex Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Days Payable Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Jun24

Days Payable

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Days Payable	Get a 7-Day Free Trial						-	-	-	-	-

Competitive Comparison of Invex Therapeutics's Days Payable

For the Biotechnology subindustry, Invex Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Days Payable falls into.

Save Embed

;

Save Embed

;

Invex Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Invex Therapeutics's Days Payable for the fiscal year that ended in Jun. 2023 is calculated as

	Days Payable (A: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2022 )	+	Accounts Payable (A: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2023 )	*	Days in Period
=	( (0.139	+	1.143)	/	2 )	/	0	*	365
=	0.641					/	0	*	365
=	N/A

Invex Therapeutics's Days Payable for the quarter that ended in Dec. 2024 is calculated as:

	Days Payable (Q: Dec. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Dec. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2024 )	*	Days in Period
=	( (0.006	+	0.48)	/	2 )	/	0	*	365 / 2
=	0.243					/	0	*	365 / 2
=	N/A

Invex Therapeutics Days Payable Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.